Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Topical Tofacitinib 2 percent ointment: Topical Tofacitinib 2 percent ointment applied over patches twice daily from Monday to Friday for 6 months
Control Intervention1: Topical Clobeta
Sponsors
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry
Eligibility
Inclusion criteria
Inclusion criteria: Clinically diagnosed active focal vitiligo with 1 percent or less body surface area involvement showing activity in the previous 3 months such as enlargement confetti lesions or trichrome changes
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding Use of systemic immunosuppressants in the prior 4 weeks Known hypersensitivity to any study drug or vehicle Rapidly progressing vitiligo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patches achieving more than 80 percent repigmentationTimepoint: 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in surface area of vitiligo patches measured with transparent graph paper planimetryTimepoint: 3 months and 6 months;Proportion of patients achieving disease stability with VSAS equal to 0Timepoint: 3 months and 6 months;Proportion of lesions achieving VNS score 4 or 5Timepoint: 3 months and 6 months;Treatment emergent adverse eventsTimepoint: Throughout study period up to 6 months | — |
Countries
India
Contacts
Public ContactDr Rashmi Kumari
JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research), Pondicherry
Outcome results
None listed